|
|
5-day change | 1st Jan Change | ||
|
65.68 USD |
-3.56% | +4.37% | +18.69% | |
Published on 06/09/2025 at 09:50
Presenter Speech
Corinne Jenkins (Analysts)
Good morning, everyone, and welcome to the Goldman Sachs Healthcare Conference. We’re thrilled to have David Meeker, the CEO of Rhythm here today joining us.
B
|
Rhythm Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 09:20 AM |
May. 14 |
|
|
Rhythm Pharmaceuticals, Inc. Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for Up to Nine Months in French Early-access Program |
May. 14 |
CI |
|
Rhythm Pharmaceuticals’ Q1 Net Loss Narrows, Revenue Increases |
May. 07 |
MT |
|
Rhythm Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 07, 2025 |
May. 07 |
|
|
Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q1 Loss $0.81, vs. FactSet Est of $0.73 Loss |
May. 07 |
MT |
|
Earnings Flash (RYTM) Rhythm Pharmaceuticals Reports Q1 Revenue $32.7M, vs. FactSet Est of $40.2M |
May. 07 |
MT |
|
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 07 |
CI |
|
Rhythm Pharmaceuticals Insider Sold Shares Worth $438,946, According to a Recent SEC Filing |
May. 01 |
MT |
|
Rhythm Pharmaceuticals Insider Sold Shares Worth $457,663, According to a Recent SEC Filing |
May. 01 |
MT |
|
Rhythm Pharmaceuticals Insider Sold Shares Worth $1,082,497, According to a Recent SEC Filing |
Apr. 10 |
MT |
|
Rhythm Pharmaceuticals Insider Sold Shares Worth $1,248,490, According to a Recent SEC Filing |
Apr. 10 |
MT |
|
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating |
Apr. 08 |
MT |
|
Rhythm Pharmaceuticals, Inc. – Special Call |
Apr. 07 |
|
|
Rhythm Pharmaceuticals’ Obesity Treatment Meets Main Goal in Phase 3 Study, Shares Rise |
Apr. 07 |
MT |
|
Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint With -19.8% Placebo-Adjusted Bmi Reduction In Patients (N=120) With Acquired Hypothalamic Obesity |
Apr. 07 |
RE |
|
Rhythm Pharma’s drug for rare obesity meets late-stage trial goal |
Apr. 07 |
RE |
|
Rhythm Pharmaceuticals’ drug for rare obesity disorder meets main goal in late-stage trial |
Apr. 07 |
RE |
|
Rhythm Pharmaceuticals Announces Pivotal Phase 3 Transcend Trial Meets Primary Endpoint with -19.8% |
Apr. 07 |
CI |
|
Rhythm Pharmaceuticals Regains Licensing Rights to Imcivree Obesity Drug |
Mar. 20 |
MT |
|
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. |
Mar. 20 |
RE |
|
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan |
Mar. 19 |
RE |
|
Rhythm Gets Orphan Drug Label for Setmelanotide in Japan |
Mar. 19 |
MT |
|
Rhythm Pharmaceuticals Insider Sold Shares Worth $3,861,272, According to a Recent SEC Filing |
Mar. 19 |
MT |
|
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration |
Mar. 18 |
CI |
|
Rhythm Pharmaceuticals, Inc. cancelled the transaction announced on December 3, 2021 |
Mar. 13 |
CI |
RYTM: Dynamic Chart
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
